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ABSTRACT 
A breach in epithelial lining from trauma or disease leads to wound formation. Wounds can 
vary in depth and can be incised, chopped, lacerated or a complex type depending upon the 
inducing agent and the direction of force applied. An untreated wound follows the natural 
course of healing that comprises of four phases. Prior to remodeling, the final phase in wound 
healing, proliferation phase initiates when the fibroblasts start depositing new extracellular 
matrix. Sometimes, the remodeling is compromised and there is excessive matrix deposition. 
This phenomenon is termed fibrosis. A number of signal transduction pathways orchestrate 
the wound healing and a disparity in the interaction leads to fibrosis. Transforming Growth 
Factor Beta (TGF-β) pathway acts as a hub in the whole interaction of wound healing and an 
abnormal response in its receptor has been confirmed to be the root cause of fibrosis. In the 
current project, TGF-β receptor was investigated as the target protein to alleviate fibrosis 
using bioinformatics tool. Briefly, the structures of TGF-β receptors were retrieved from 
PDB. A series of natural and synthetic drugs were searched and the corresponding structures 
were retrieved from PUBCHEM database. Ligand-receptor docking was done using Swiss-
dock software. The structure of best docked ligand i.e. α-tocopherol was modified in 
ChemSketch followed by docking. Both virgin and the modified α-tocopherol can act as 
novel drug against excessive fibrosis; however it needs final validation in vitro and in vivo. 
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1. INTRODUCTION 
A wound occurs when there is injury to a tissue (e.g. skin break, muscle tear/burn or a bone 
fractures). Wounds are the outcome of external physical trauma. The most common causes of 
wounds are vehicle accidents, falls and the misuse of sharp objects, tools, machinery, 
weapons, a surgical procedure, an infectious disease or an underlying pathological condition.
 
[1] 
1.1. Types of Wound 
Wounds are classified as open or closed. An open wound is a break in the skin or in a mucous 
membrane. A closed wound involves underlying tissues without a break in the skin or a 
mucous membrane. Wounds are of various types and have different causes, based on which 
there are several ways of classifying them.
 [2]
 
Wounds are of the following types: - 
 Abrasions (scrapes) – skin rubbed away due to frictional force. [1] 
 Avulsions – forced removal of tissue from body. [1] 
 Lacerations – blunt and irregular breaks due to use of high force. [1] 
 Punctures – narrow and deep wound due to penetration of sharp objects like a pin. [1] 
 Incisions – sharp cut due to sharp instrument. [1] 
 Contusions – internal injury due to forced trauma. [1] 
1.2. Mechanism of Wound Healing 
Wound healing is a continuously changing, difficult to understand phenomenon in which the 
wounded area changes with respect to the health of the individual. The idea about normal 
wound healing process through the phases of hemostasis, inflammation, granulation and 
maturation provides a framework for an understanding of the basic principles of wound 
healing. Through this understanding the health care professional can develop the skills 
required to care for a wound and the body can be assisted in the complex task of tissue repair.
 
[2]
 
A chronic wound should prompt the health care professional to begin a search for unresolved 
underlying causes. Healing a chronic wound requires care that is patient centered, holistic, 
interdisciplinary and cost-effective and evidence based. 
[2] 
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1.2.1. Phases of Wound Healing 
Based on research, both acute wounds and  heals chronic wounds follow four basic phases 
[2]
 
as described below: - 
 Hemostasis – During an injury, healing process starts as blood platelets at the 
site of injury comes in contact with extracellular matrix which leads to the 
release of growth factors and cytokines such as platelet-derived growth factor 
(PDGF) and transforming growth factor beta (TGF-ß). 
[3]
 
 Inflammation – The neutrophils as well as the macrophages come to the site 
and remove the foreign materials, microbes and damaged tissues by 
phagocytosis releasing more PDGF and TGF-ß, paving the way for 
proliferation phase to start. 
[3]
 
 Proliferation or Granulation – After cleaning of the wound site fibroblasts 
reach the wound site and deposit new extracellular matrix. 
[3]
 
 Remodeling or Maturation – The new collagen matrix becomes cross-linked 
and organized during this stage. 
[3]
 
1.2.2. Signal Transduction Pathways in Wound Healing 
There are numerous signaling pathways involved in the complicated and dynamic, repairing 
process of wound healing. During wound healing, by the time Proliferation stage starts, 
fibroblasts have started depositing extracellular matrix. Fibrosis is the result of the surplus 
expression of extracellular matrix by fibroblast during that stage. The extracellular matrix 
deposited is mostly composed of collagen expressed by the reaction of different growth 
factors - TGF-β, PDGFs, IGF, CTGF and TNF’s. But the Inhibition of collagen secretion is 
dependent on TGF-β. In this study the main receptors of TGF-β pathway were studied and 
various natural and currently used synthetic drugs were used to determine their binding with 
the receptors, which could lead to the finding of a new drug for the treatment of fibrosis. 
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The initial phase of the repair 
reaction typically begins with 
hemorrhage into the tissues.  
(1) A fibrin clot forms and fills the 
gap created by the wound. 
Fibronectin in the extravasated 
plasma is cross-linked to fibrin, 
collagen, and other extracellular 
matrix components by the action of 
transglutaminases. This cross-
linking provides a provisional 
mechanical stabilization of the 
wound (0–4 hours). 
 
(2) Macrophages recruited to the 
wound aea process cell remnants 
and damaged extracellular matrix. 
The binding of fibronectin to cell 
membranes, collagens, 
proteoglycans, DNA and bacteria 
(opsonization) facilitates 
phagocytosis by these macrophages 
and contribute to the removal of 
debries. 
 
(3) Fibronectin, cell debris, and 
bacterial products are chemo-
attractants for a variety of cells that 
are recruited to the wound site (2–4 
days).  
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The intermediate phase of the 
repair reaction; 
 
(4) As a new extracellular matrix 
is deposited at the wound site, the 
initial fibrin clot is lysed by a 
combination of extracellular 
proteolytic enzymes and 
phagocytosis (2–4 days).  
 
 
 
(5) Concurrent with fibrin 
removal, there is deposition of a 
temporary matrix formed by 
proteoglycans, glycoproteins, and 
type III collagen (2–5 days).  
 
 
 
 
(6) Final phase of the repair 
reaction. Eventually the 
temporary matrix is removed by a 
combination of extracellular and 
intracellular digestion, and the 
definitive matrix, rich in type I 
collagen, is deposited (5 days–
weeks). 
 
      Figure -1: -Summary of the healing process 
[5]
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2. LITERETURE REVIEW 
2.1. Transforming Growth Factor β (TGF-β) and Fibrosis: 
Transforming growth factor beta (TGF-β) is a cytokine that mediates cellular differentiation 
by controlling signal transduction pathways. In addition it has an wide range of functions that 
include immune function, oncogenesis and the pathophysiology of heart disease, diabetes, 
Marfan syndrome. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 - Solution structure of TGF-β1 
 
TGF-β has three isoforms called TGF-β1, TGF-β2 and TGF-β3. TGF-β acts as tumor 
suppressive factor at early stages of oncogenesis. Some cells secrete TGF-β secreted by some 
cells can act on the same cell through the expression of its own receptor. Such autocrine 
signaling increases the production of TGF-β, which also acts on the surrounding cells. 
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2.2. TGF-β ACTIVATION 
TGF-β ligand upon activation will initiate the TGF-β signaling cascade depending upon the 
availability of TGF-β receptors I and II due to high affinity between TGF-β and its receptors. 
Thus, TGF-β signaling recruits a latency system for cell signaling. [4] Such activation of TGF-
β is found to be dependent on reactive oxygen species, pH and proteases. 
TGF-β Pathway  
 
Figure 3 – TGF-β Family Core Pathway [6] 
Transforming growth factor (TGF) beta superfamily comprises of over 30 members including 
Activins, Nodals, Bone Morphogenetic Proteins (BMPs), and Growth and Differentiation 
Factors (GDFs). The signaling of the TGF–β superfamily is through ligand binding to the 
serine/threonine kinase receptors which gives signal to Smad protein, and the gene expression 
in the nucleus starts. 
[6]
 
Signals for TGF-beta superfamily members are transmitted through heteromeric complexes 
comprised of type I and II trans-membrane serine/threonine kinase receptors.
 [6]
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2.3. TGF-Β receptors 
 TGF-β Receptor, Type I 
 
Figure-4: - Crystal Structure of TGF-beta receptor I kinase with inhibitor (1PY5)  
 TGF-β Receptor, Type II 
 
Figure-5: - Crystal Structure of Human TGF-Beta type II receptor ligand binding 
domain (1m9z) 
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3.1. Tools used 
Swiss PDB Viewer – “http://www.expasy.org/spdbv” 
To view the PDB structures of the compounds and ligands and for energy minimization. For 
energy minimization the following steps were followed – 
 In menu bar – Select > all 
 Tools > energy minimization 
 Ctrl + S > save as “own required file name” 
 
Figure 6 – SWISS PDB VIEWER 
PUBCHEM – “http://pubchem.ncbi.nlm.nih.gov/” 
This database is a collection of cross-checked molecule structures which was used to retrieve 
all the ligands used in this study. 
 
Figure 7 - PUBCHEM 
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Protein Data Bank – “http://www.rcsb.org/pdb/home/home.do” 
Online database of biological macromolecules found worldwide which was used to retrieve 
the structure of the receptor molecules. 
 
Figure 8 – Protein Data Bank 
 
ARGUS LAB  
Molecular viewer software used to view edit and dock ligands to the receptors. It was used to 
optimize the geometry of modified molecule. 
 
Figure 9 – Argus lab 
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UCSF CHIMERA   
Powerful molecular viewer software providing data on docked structure by use of 
VIEWDOCK extension. This software was used to view the .chimerax extension file 
provided by the SWISSDOCK (on-line docking server) which provided the Binding energy 
results. 
 
Figure 10 - UCSF CHIMERA 
CHEMSKETCH  
Software used to draw chemical structure easily and calculate their properties. This software 
was used to remove the CH3 groups and insert OH groups instead to create synthetic drugs for 
testing. 
 
Figure 11- CHEMSKETCH 
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SWISSDOCK ONLINE DOCKING – “http://swissdock.vital-it.ch/docking” 
This online docking server was used to dock the selected ligands with the receptors and 
provided Binding energy results. 
 
Figure 12- SWISSDOCK online docking 
 
OPEN BABEL  
Software used for converting various molecular file formats, example – converting .mol file 
to .pdb file. 
 
Figure 13 - BABEL
14 
 
3.2. Plan of Work 
 
 
 
24 natural ligands and 5 synthetic 
ligands selected and retrieved from 
PUBCHEM 
TGF-β receptor I & TGF-β receptor II 
structures  retrieved from PROTEIN 
DATA BANK 
Receptor-Ligand Docking done using  
SWISSDOCK ONLINE DOCKING 
SERVER 
The results were viewed using chimera 
and comparision based on natrural and 
synthetic drugs were made. 
3 Ligands showing minimum binding 
energy were selected [natural sources] 
Their structure was edited using 
chemsketch and ADMET prediction 
was done 
The modified ligands were again 
docked with the receptors and compared 
with synthetic ligands docking results  
The best ligand/inhibitor was porposed 
15 
 
3.3. Procedure 
1. Structure Retrieval –  
All the structures of drugs/ligands were retrieved from PUBCHEM and conversion to 
required file format was done using BABEL.The structures of the receptors were retrieved 
from PROTEIN DATA BANK in the form of .pdb file format. 
2. Docking –  
The downloaded ligand files were docked with the receptor to find the best ligand with most 
stability, i.e. minimum binding energy. The docking was done using SWISS DOCK ONLINE 
SERVER. 
3. Selection of Ligands – 
 From the binding energies obtained, three molecules with the lowest binding energy were 
selected (from the 24 natural drugs) as natural treatment for fibrosis. 
4. Ligand Modification and ADMET prediction–  
The three molecules were then modified using CHEMSKETCH by removing their methyl 
groups and adding oh group at that place. These modified drugs were then placed under 
ADMET prediction for Aerobic Biodegradability, Ames Mutagenicity, Developmental 
Toxicity Potential and Ocular Irritancy Mild vs. Moderate Severe. 
5. Docking with Modified Ligand –  
From the modified drugs the drug with the lowest toxicity was selected and docked with the 
receptors to find its binding energy with the receptors.  
16 
 
3.4. List of Drugs Used 
Table 1: List of Natural Ligands of TGF-β receptors  
Name of Drug 
(Natural 
Ligand) 
Pubchem 
(i.d.) 
Molecular 
Weight 
Molecular 
Formula 
Structure 
 
Lysine 
 
CID 5692 
 
146.18756  
 
C6H14N2O2 
 
 
Cycloallin 
 
CID 19329
4 
 
177.22144 
 
C6H11NO3S 
 
 
Curcumin 
 
CID 
5281767 
 
368.3799 
 
C21H20O6 
 
 
Turmerone 
 
CID 
14367555 
 
218.33458 
 
C15H22O  
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Verbenalin 
 
CID 73467 
 
388.36646 
 
C17H24O10 
 
 
Alphalipoic 
acid 
 
CID 
445125 
 
206.32556 
 
C15H22O 
 
 
1,2 – Dithiolane 
-3- Valric 
 
CID 864 
 
206.32556 
 
C8H14O2S2 
 
 
Glucosamine 
 
CID 
441477 
 
179.17112 
 
C6H13NO5 
 
 
Alpha 
tocopherol 
(Vitamin E) 
 
CID 14985 
 
430.7061 
 
C29H50O2 
 
18 
 
 
Eugenol 
 
CID 3314 
 
164.20108 
 
C10H12O2 
 
 
Linalool 
 
CID 6549 
 
154.24932 
 
C10H18O 
 
 
Catechin 
 
CID 9064 
 
290.26806 
 
C15H14O6 
 
 
Carracrol 
 
CID 10364 
 
150.21756 
 
C10H14O 
 
 
Elemene 
 
CID 10583 
 
204.35106 
 
C15H24 
 
19 
 
 
Proanthocyanid
in A 
 
CID 
108065 
 
592.54682 
 
C31H28O12 
 
 
Laminaribose 
 
CID 
25245814 
342.29648 C12H22O11 
 
 
Ajmalicine 
 
CID 
251561 
352.42686 C21H24N2O3 
 
 
Swertiamarin 
 
CID 
114700 
 
374.33988 
 
C16H22O10 
 
 
Apigenin 
 
CID 
5280443 
 
270.2369 
 
C15H10O5 
 
20 
 
 
 
 
Luteolin 
 
CID 
5280445 
 
286.2363 
 
C15H10O6 
 
 
Caryophyllene 
 
CID 
5281515 
 
204.35106 
 
C15H24 
 
 
Myricetin 
 
CID 
5281672 
 
318.2351 
 
C15H10O8 
 
 
Rosmarinic 
Acid 
 
CID 
5281792 
 
360.31484 
 
C18H16O8 
 
 
Germacrene A 
 
CID 
9548705 
 
204.35106 
 
C15H24 
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Table 2: List of Synthetic Ligands of TGF β receptors 
  
NAME OF 
DRUG(LIGAND) 
[NATURAL] 
PUBCHEM 
ID 
MOLECULAR 
WEIGHT 
MOLECULAR 
FORMULA 
STRUCTURE 
 
Azothioprine 
 
CID 2265 
 
277.26258 
 
C9H7N7O2S 
 
 
Colchicine 
 
CID 6167 
 
399.437 
 
C22H25NO6 
 
 
Cyclophospha
mide 
 
CID 2907 
 
261.085962 
 
C7H15Cl2N2O2P 
 
Mycophenolate 
Mofetil 
CID 
5281078 
433.49474 C23H31NO7 
 
 
Pirfenidone 
 
CID 40632 
 
185.22184 
 
C12H11NO 
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4. Results and Discussions 
4.1. Ligand (Unmodified)-Protein Docking Result 
Receptor and ligand were docked using SWISSDOCK online server. The results obtained 
are: - 
Table 3: Binding energy of Natural Ligands Following Docking 
Name of Drug  
(Natural Ligand) 
ΔG (Kcal/Mol) Receptor   
1 
ΔG (Kcal/Mol) Receptor 
2 
Lysine -7.0551524 -5.9956436 
Cycloallin -6.8762417 -6.046295 
Curcumin -9.070615 -7.160752 
Turmerone -6.8523955 -6.253523 
Verbenalin -8.317615 -6.9071236 
Alpha lipoic acid -7.7582974 -6.269606 
1,2 – Dithiolane -3- Valric -7.578595 -6.4135394 
Glucosamine -6.9926643 -6.1596193 
Alpha tocopherol (Vitamin E) -8.713398 -6.3799357 
Eugenol -7.01427 -5.9118385 
Linalool -6.5363007 -5.932526 
Catechin -8.092369 -6.487141 
Carracrol -6.768245 -5.8302073 
Elemene -6.8595595 -6.1184897 
Proanthocyanidin A -7.698849 -6.7706394 
Laminaribose -8.582201 -6.893973 
Ajmalicine -7.6328998 -6.258801 
Swertiamarin -8.659184 -6.737429 
Apigenin -7.9015365 -6.3797035 
Luteolin -8.022708 -6.398905 
Caryophyllene -7.0452323 -5.9958153 
Myricetin -7.99371 -6.437615 
Rosmarinic Acid -9.114415 -7.218021 
Germacrene A -6.4372272 -5.961119 
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Table 4: Binding energy of Synthetic Ligands Following Docking 
Name of Drug 
(Synthetic Ligand)  
ΔG (Kcal/Mol) Receptor  
1 
ΔG (Kcal/Mol) Receptor  
2 
Azothioprine -7.630012 -6.602702 
Colchicine -6.9731503 -6.1768827 
Cyclophosphamide -7.2774844 -6.303278 
Mycophenolate Mofetil -9.018024 -6.849458 
Pirfenidone -6.868995 -6.028638 
 
The Three molecules with best binding energy are 
Table 5: Binding Energy Of Best Three Ligands 
 
Name of Drug 
(Natural Ligand)  
ΔG 
(Kcal/Mol) 
Receptor 1 
Name of Drug 
(Natural Ligand) 
ΔG (Kcal/Mol)  
Receptor 2 
Rosmarinic Acid -9.114415 Rosmarinic Acid -7.218021 
Curcumin -9.070615 Curcumin -7.160752 
Alpha tocopherol (Vitamin E) -8.713398 Verbenalin -6.9071236 
 
On Comparing Binding energy values of the selected drugs with those of synthetic drugs it 
was found that the selected (best 3) natural drugs have much better binding energy than those 
of the synthetic drugs. These drugs can be selected as inhibitor for TGF-β pathway. 
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FIGURE 14 – Rosmarinic Acid docked with Receptor II 
 
FIGURE 15 - Rosmarinic Acid docked with Receptor 1 
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4.2. Ligand Modification and Toxicity Testing 
The drugs Curcumin, Alpha Tocopherol & Verbenalin were selected for modification. 
They were modified by removing Methyl group and adding OH group instead using 
chemsketch. 
The toxicity of the modified molecules was tested using ADMET predictions. 
ADMET Prediction 
 
Figure 16- Modified Ligands 
Table 6: The Toxicity Report of Ligands from ADMET Server 
Molecule Modified 
Structure 
Biodegradability Toxicity Mutagenicity Ocular 
Irritancy 
Curcumin Fig.16(a) Residues are 
degradable 
Residues are 
highly toxic 
Residues are 
non-mutagenic 
Highly irritant 
α-tocopherol Fig.16(b) Residues are 
degradable 
The 
prostaglandin 
residue is 
non-toxic 
Residues are 
non-mutagenic 
Irritant (cannot 
be used for eye 
scars.) 
Verbenalin Fig.16(c) Residues are 
degradable 
All residues 
are toxic 
One residue is 
non-mutagenic 
Highly Irritant 
 
Since, Alpha Tocopherol (modified) was the most favorable one it was selected for docking 
with both the receptors. 
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4.3. Ligand (modified)-Protein Docking Result 
After docking the results are as follows: - 
With Receptor 1- ΔG = -15.824196 Kcal/Mol 
With Receptor 2 - ΔG = -13.08529 Kcal/Mol 
Thus, this drug is providing better binding energy results than the natural and synthetic drugs 
considered above. It can be used to treat fibrosis, but prior to that in-vitro testing should be 
done. 
 
Docked Structures [Ligand (modified)-Protein] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 –Vitamin E (modified) 
docked with Receptor II 
 
Figure 18– Vitamin E (modified) 
docked with Receptor 1 
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Conclusions 
The natural drugs were tested under in silico condition and a drug with better binding result 
was shown as compared to the synthetic drugs. On the other hand, modifying it provided with 
a drug with better result. Hence, it can be said that in silico testing should be done for better 
results both capital and time are saved. 
Base on the in silico experimentation the following drugs can be used as potential novel 
drugs for the prevention of fibrosis –  
Natural - Rosmarinic Acid 
ΔG (Kcal/Mol) Receptor 1= -9.114415 Kcal/Mol  
ΔG (Kcal/Mol) Receptor 2= -7.218021 Kcal/mol 
Synthetic - Mycophenolate Mofetil 
ΔG (Kcal/Mol) Receptor 1= -9.018024 Kcal/mol 
` ΔG (Kcal/Mol) Receptor 2= -9.018024 Kcal/mol 
Modified - Alpha-tocopherol (modified) 
ΔG (Kcal/Mol) Receptor 1= -15.824196 Kcal/Mol 
ΔG (Kcal/Mol) Receptor 2= -13.08529 Kcal/Mol 
However, before formulating an effective drug the above molecules need both in vitro and in 
vivo validation. 
 
Future Work 
Future work could be the in-vitro preparation as well as testing of the drugs on fibrotic cells 
before making any conclusions about how good the drug is. This may include culturing of 
fibrotic cells and testing of the drugs on them. 
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